Skip to Main Content

Paper Details

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells.
Elife
32
2020
CAR, CD8, NK cell, NK cells, PD, PD-L1, PD-L1 chimeric antigen receptor, Tumor, chimeric antigen receptor modified NK cells, haNKs, head and neck cancer, human, immunosuppressive myeloid populations, macrophages, murine, murine head and neck cancer cells, myeloid cells, patients, syngeneic tumors, xenograft
Author NameAffiliation
Carter Van WaesNational Institute on Deafness and Other Communication Disorders, National Institutes of Health
Carter Van WaesNational Institute on Deafness and Other Communication Disorders, National Institutes of Health
  • 1 - 2

Datasets

Release 1.2